If a patient has a mutation that impairs the production of thromboxane A2 in platelets, which consequence is most likely?

💡 Explanation

Reduced thromboxane A2 impairs the platelet activation and aggregation needed for clot formation because thromboxane A2 amplifies the initial platelet response during hemostasis. Therefore, reduced production leads to impaired clotting, rather than enhanced clotting or effects on other blood cell types or clot breakdown.

• Why does polyspermy generally fail to produce viable human embryos after in vitro fertilization?
• If a person experiences hypocalcemia, and the voltage-gated sodium channels of the neuromuscular junction become more sensitive, which consequence follows?
• A patient with a genetic defect has impaired cytotoxic T lymphocyte (CTL) function. Why does this deficiency increase the risk of virally induced tumors?
• If a patient's thyroid gland is exposed to radioactive iodine, which consequence follows regarding thyroid hormone production?
• If a drug exhibits significant first-pass metabolism following oral administration, which consequence follows, necessitating a higher dose compared to intravenous administration?
• Why does chronic use of tactile desensitization creams, like those containing high concentrations of benzocaine, increase the risk of accidental injury in patients?